Serum paraoxonase activity in patients with rheumatoid arthritis, its relationship with the clinical course and cardiovascular compications

  • S. V. Shevchuk National Pirogov Memorial Medical University
  • Y. S. Seheda National Pirogov Memorial Medical University
  • O. Y. Galyutina National Pirogov Memorial Medical University
  • N. P. Masik National Pirogov Memorial Medical University
  • O. V. Shevchuk National Pirogov Memorial Medical University
Keywords: enzyme activity; autoimmune disease; metabolic risk factors; changes of the cardiovascular system

Abstract

Nowadays low paraoxonase activity is generally recognized as an independent risk factor of cardiovascular diseases involved in pathologic remodeling of the heart and vessels as well as thrombosis in the general population. But the role of paraoxonase activity in RA patients is unknown. Based on the above, the aim of the work was to study serum paraoxonase activity in patients with rheumatoid arthritis, to evaluate its association with clinical course and structural and functional status of the cardiovascular system. 67 patients with RA, 18 males and 49 females were studied. The control group consisted of 25 apparently healthy individuals. Rheumatoid arthritis was diagnosed according to international classification criteria ACR 2012. The indices of total cholesterol (TC), high density lipoprotein cholesterol (HDLC) and triglycerides (TG) in blood serum were determined by standard conventional methods. Low density lipoprotein cholesterol (LDLC) values were calculated by Friedwald formula. Serum paraoxonase activity was measured by spectrophotometric method. High resolution ultrasound and Doppler ultrasonography of the brachial artery were performed to study endothelium function. Sonographic B-mode scanning and pulsed Doppler ultrasound of heart and blood flow spectra were done on ultrasound scanner. Serum paraoxonase activity was found to be about 18.8% lower in the patients with RA than in the control group. Serum paraoxonase activity was shown to decrease proportionally to the increase of the age in RA patients. In the group of patients over 45, the level of the enzyme was 13.0% lower than in the patients over 30. The study established that the increase of systolic and diastolic arterial pressure is associated with decrease of serum paraoxonase activity in RA patients. The patients with RA combined with arterial hypertension had significantly (by 10.9%) lower activity of the studied enzyme than those with no arterial hypertension. However, no significant relationship between paraoxonase activity and duration of the disease, obesity and smoking was revealed. Paraoxonase activity in RA patients was demonstrated to be dependent on lipid levels. The lowest paraoxonase activity was recorded in individuals with the highest levels of TC, LDLC and the lowest HDLC indices. Paraoxonase activity in RA patients is associated not only with atherosclerotic vascular damage (IMT, decreased FMDBA) but also with structural and functional heart status (systolic and diastolic functions, left ventricular myocardial hypertrophy). Decreased serum paraoxonase level is suggested to be the predictor of early development of cardiovascular complications in RA patients.

References

Bernardes, M., Vieira, T. S., Martins, M. J., Lucas, R., Costa, L., Pereira, J. G., Ventura, F., & Martins, E. (2017) Myocardial perfusion in rheumatoid arthritis patients: Associations with traditional risk factors and novel biomarkers. BioMed Research International, 2017, 1.


Bounafaa, A., Berrougui, H., Ghalim, N., Nasser, B., Bagri, A., Moujahid, A., Ikhlef, S., Camponova, P., Yamoul, N., Simo, O. K., Essamadi, A., & Khalil, A. (2015). Association between paraoxonase 1 (PON1) polymorphisms and the risk of acute coronary syndrome in a North African population. PLoS One, 10(8), e0133719.


Celermajer, D. S., Sorensen, K. E., & Gooch, V. M. (1992). Non-invasive detection of endothelial disfunction in children and adults at risk of atherosclerosis Lancet, 340(8828), 1111–1115.


Charles-Schoeman, C., Lee, Y. Y., Shahbazian, A., Gorn, A. H., Fitzgerald, J., Ranganath, V. K., Taylor, M., Ragavendra, N., McMahon, M., Elashoff, D., & Reddy, S. T. (2013). Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis and Rheumatology, 65(11), 2765–2772.


Connelly, P. W., Maguire, G. F., & Draganov, D. I. (2004) Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity. Journal of Lipid Research, 45(3), 561–566.


El-Banna, H., & Jiman-Fatani, A. (2014). Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis. BMC Musculoskeletal Disorders, 15(1), 379.


Hashemi, M., Moazeni-Roodi, A. K., Fazaeli, A., Sandoughi, M., Bardestani, G. R., Kordi-Tamandani, D. M., & Ghavami, S. (2010). Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genetics and Molecular Research, 9(1), 333–339.


Herly, M., Stengaard-Pedersen, K., Hørslev-Petersen, K., Hetland, M. L., Østergaard, M., Christensen, R., Løgstrup, B. B., Vestergaard, P., Pødenphant, J., Junker, P., & Ellingsen, T. (2017). Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the Cimestra trial: Protocol for a cohort study with patient-record evaluated outcomes. British Medical Journal Open, 7(4), e014816.


Isik, A., Koca, S. S., Ustundag, B., Celik, H., & Yildirim, A. (2007) Paraoxonase and arylesterase levels in rheumatoid arthritis. Clinical Rheumatology, 26(3), 342–348.


Kay, J., & Upchurch, K. S. (2012). ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford), 51(6), vi5–9.


Kerekes, G., Szekanecz, Z., Dér, H., Sándor, Z., Lakos, G., Muszbek, L., Csipö, I., Sipka, S., Seres, I., Paragh, G., Kappelmayer, J., Szomják, E., Veres, K., Szegedi, G., Shoenfeld, Y., & Soltész, P. (2008). Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. The Journal of Rheumatology, 35(3), 398–406.


Kim, D. S., Li, Y. K., Bell, G. A., Burt, A. A., Vaisar, T., Hutchins, P. M., Furlong, C. E., Otvos, J. D., Polak, J. F., Arnan, M. K., Kaufman, J. D., McClelland, R. L., Longstreth, W. T. Jr., & Jarvik, G. P. (2016). Concentration of smaller high-density lipoprotein particle (HDL-P): Is inversely correlated with carotid intima media thickening after confounder adjustment: The multi ethnic study of atherosclerosis (MESA). Journal of the American Heart Association, 5(5), e002977.


Kiss, E., Seres, I., & Tarr, T. (2007). Reduced paraoxonase 1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Annals of the New York Academy of Sciences, 1108, 83–91.


Kulka, M. (2016). A review of paraoxonase 1 properties and diagnostic applications. Polish Journal of Veterinary Science, 19(1), 225–232.


Kunutsor, S. K., Bakker, S. J., James, R. W., & Dullaart, R. P. (2016). Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The Prevend study and meta-analysis of prospective population studies. Atherosclerosis, 245, 143–154.


Ladak, K., Hashim, J., Clifford-Rashotte, M., Tandon, V., Matsos, M., & Patel, A. (2017). Cardiovascular risk management in rheumatoid arthritis: A large gap to close. Musculoskeletal Care, 18.


Meissner, Y., Richter, A., Manger, B., Tony, H. P., Wilden, E., Listing, J., Zink, A., & Strangfeld, A. (2017). Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: Results from the German Rabbit cohort. Annals of the Rheumatic Diseases, 76(9), p1583–1590.


Myasoedova, E., Gabriel, S. E., Matteson, E. L., Davis, J. M., Therneau, T. M., & Crowson, C. S. (2017). Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: Dawn of a new era in cardiovascular disease in RA? The Journal of Rheumatology, 44(6), 732–739.


Patra, S. K, Singh, K., & Singh, R. (2013). Paraoxonase 1: A better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes and Metabolic Syndrome, 7(2), 108–111.


Rodríguez-Carrio, J., Alperi-López, M., López-Mejías, R., López, P., Ballina-García, F. J., Abal, F., González-Gay, M. Á., & Suárez, A. (2016). Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis. Clinical Science, 130(21), 1889–1899.


Sayın Kocakap, D. B., Doğru, M. T., Şimşek, V., Çabuk, F., Yıldırım, N., Çelik, Y., Alyılmaz Bekmez, S., & Erdem, S. (2016). The association of paraoxonase 1 gene L55M polymorphism with the extent and severity of coronary artery disease in the Turkish population and its dependence on gender. Anatolian Journal of Cardiology, 16(3), 175–182.


Shahmohamadnejad, S., Vaisi-Raygani, A., Shakiba, Y., Kiani, A., Rahimi, Z., Bahrehmand, F., Shakiba, E., & Pourmotabbed, T. (2015) Association between butirilcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: Correlation with systemic inflammatory markers and oxidative stress, preliminary report. Clinical Biochemistry, 48(1–2), 63–69.


Tanimoto, N., Kumon, Y., Suehiro, T., Ohkubo, S., Ikeda, Y., Nishiya, K., & Hashimoto, K. (2003). Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sciences, 72(25), 2877–2885.


Tang, W. H., Hartiala, J., Fan, Y., Wu, Y., Stewart, A. F., Erdmann, J., Kathiresan, S. CARDIoGRAM Consortium, Roberts, R., McPherson, R., Allayee, H., & Hazen, S. L. (2012). Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(11), 2803–2812.


Tocci, G., Goletti, D., Marino, V., Matucci, A., Milano, G. M., Cantini, F., & Scarpa, R. (2016). Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: A focus on rheumatoid arthritis. Expert Opinion on Drug Safety, 15(1), 55–61.


Wang, F., Liu, Y., Cong, Y., Li, P., Li, Y., Yan, Z. Tang, Y., Cheng, Y., & Zheng, Y. (2015). Shift of the interconnection from the reaction system of paraoxonase 1 to the peroxidation reaction system of myeloperoxidase with HDL-C levels: A marker of atherosclerosis in patients with normal cholesterol levels. Clinica Chimica Acta, 438, 370–375.


Wendelhag, I., Wiklund, O., & Wikstrand, J. (1993). Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plague occurrence. Arteriosclerosis and Thrombosis, 13, 1404–1411.


Yang, X., Gao, F., & Liu, Y. (2015). Association of homocysteine with immunological-inflammatory and metabolic laboratory markers and factors in relation to hyperhomocysteinaemia in rheumatoid arthritis. Clinical and Experimental Rheumatology, 33(6), 900–903.


 

Published
2018-02-17
How to Cite
Shevchuk, S. V., Seheda, Y. S., Galyutina, O. Y., Masik, N. P., & Shevchuk, O. V. (2018). Serum paraoxonase activity in patients with rheumatoid arthritis, its relationship with the clinical course and cardiovascular compications. Regulatory Mechanisms in Biosystems, 9(1), 90-94. https://doi.org/10.15421/021813